Bersavine: A Novel Bisbenzylisoquinoline Alkaloidwith Cytotoxic, Antiproliferative and Apoptosis-Inducing Effects on Human Leukemic Cells.
antiproliferative activity
apoptosis
bersavine
cell cycle
cytotoxicity
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
20 Feb 2020
20 Feb 2020
Historique:
received:
20
01
2020
revised:
18
02
2020
accepted:
19
02
2020
entrez:
26
2
2020
pubmed:
26
2
2020
medline:
20
11
2020
Statut:
epublish
Résumé
Bersavine is the new bisbenzylisoquinoline alkaloid isolated from the Berberis vulgaris L.(Berberidaceae) plant. The results of cytotoxicity screening 48 h post-treatment showed thatbersavine considerably inhibits the proliferation and viability of leukemic (Jurkat, MOLT-4), colon(HT-29), cervix (HeLa) and breast (MCF-7) cancer cells with IC50 values ranging from 8.1 to 11 μM.The viability and proliferation of leukemic Jurkat and MOLT-4 cells were decreased after bersavinetreatment in a time- and dose-dependent manner. Bersavine manifested concentration-dependentantiproliferative activity in human lung, breast, ovarian and hepatocellular carcinoma cell linesusing a xCELLigence assay. Significantly higher percentages of MOLT-4 cells exposed to bersavineat 20 μM for 24 h were arrested in the G1 phase of the cell cycle using the flow cytometry method.The higher percentage of apoptotic cells was measured after 24 h of bersavine treatment. Theupregulation of p53 phosphorylated on Ser392 was detected during the progression of MOLT-4 cellapoptosis. Mechanistically, bersavine-induced apoptosis is an effect of increased activity ofcaspases, while reduced proliferation seems dependent on increased Chk1 Ser345 phosphorylationand decreased Rb Ser807/811 phosphorylation in human leukemic cells.
Identifiants
pubmed: 32093423
pii: molecules25040964
doi: 10.3390/molecules25040964
pmc: PMC7071104
pii:
doi:
Substances chimiques
Alkaloids
0
Antineoplastic Agents, Phytogenic
0
Cytotoxins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Union
ID : CZ.02.1.01/0.0/0.0/18_069/0010046
Organisme : Charles University
ID : Progres/UK Q40/01
Organisme : Charles University
ID : SVV-260397/2017
Références
J Zhejiang Univ Sci B. 2011 Jul;12(7):568-74
pubmed: 21726064
Cytotechnology. 2018 Feb;70(1):321-329
pubmed: 28965196
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2009 Sep;38(5):439-44
pubmed: 19830854
Curr Med Chem. 2018;25(38):5088-5114
pubmed: 28933285
Sci Rep. 2017 Jul 19;7(1):5806
pubmed: 28724926
J Med Chem. 2008 May 8;51(9):2589-99
pubmed: 18393402
Lancet Oncol. 2018 Mar;19(3):293-294
pubmed: 29508748
Prostate Cancer Prostatic Dis. 2016 Dec;19(4):358-366
pubmed: 27431500
J Nat Prod. 2019 Feb 22;82(2):239-248
pubmed: 30701972
Acta Pharmacol Sin. 2009 Dec;30(12):1659-65
pubmed: 19960011
Alkaloids Chem Biol. 2019;82:147-304
pubmed: 30850031
Asian Pac J Cancer Prev. 2014;15(4):1767-9
pubmed: 24641406
Evid Based Complement Alternat Med. 2017;2017:8152526
pubmed: 28883885
J Zhejiang Univ Sci B. 2007 Apr;8(4):248-55
pubmed: 17444599
J Asian Nat Prod Res. 2009;11(3):219-28
pubmed: 19408145
Oncol Res. 2013;20(7):265-74
pubmed: 23879166
Anat Rec (Hoboken). 2014 May;297(5):802-9
pubmed: 24619961